Payment overview · 2025
General Payments
$624.21
33 reported records · 10 companies
Healthcare provider profile · identity verified
John Paul Lee, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FOREST, MS · NPI 1992806699
Verified facts
What the public records show
CMS Open Payments records show John Paul Lee, M.D. received $624.21 in general payments during 2025 across 33 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $200.05 | 32.0% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $170.99 | 27.4% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $86.85 | 13.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.81 | 8.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.15 | 5.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.24 | 3.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.23 | 3.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.13 | 2.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.22 | 2.3% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $13.54 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $624.21 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $163.80 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $130.60 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $86.85 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $69.45 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.81 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.54 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.57 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 115 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
115 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 823 | 257 |
| Atorvastatin Calcium | Atorvastatin Calcium | 746 | 241 |
| Omeprazole | Omeprazole | 506 | 161 |
| Lisinopril | Lisinopril | 405 | 117 |
| Losartan Potassium | Losartan Potassium | 402 | 116 |
| Hydrochlorothiazide | Hydrochlorothiazide | 381 | 141 |
| Furosemide | Furosemide | 377 | 112 |
| Metformin Hcl | Metformin Hcl | 356 | 105 |
| Gabapentin | Gabapentin | 314 | 102 |
| Spironolactone | Spironolactone | 289 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 64 |
| Allopurinol | Allopurinol | 185 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 47 |
| Amoxicillin | Amoxicillin | 179 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 57 |
| Potassium Chloride | Potassium Chloride | 171 | 51 |
| Glimepiride | Glimepiride | 169 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 148 | 46 |
| Carvedilol | Carvedilol | 136 | 41 |
| Eliquis | Apixaban | 136 | 28 |
| Mirtazapine | Mirtazapine | 132 | 34 |
| Prednisone | Prednisone | 129 | 84 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 38 |
| Farxiga | Dapagliflozin Propanediol | 115 | 26 |
| Jardiance | Empagliflozin | 107 | 17 |
| Sertraline Hcl | Sertraline Hcl | 106 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 62 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 22 |
| Betamethasone Valerate | Betamethasone Valerate | 79 | 48 |
| Trazodone Hcl | Trazodone Hcl | 76 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 27 |
| Ozempic | Semaglutide | 72 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 64 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 23 |
| Simvastatin | Simvastatin | 66 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 20 |
| Famotidine | Famotidine | 60 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Azithromycin | Azithromycin | 59 | 47 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 17 |
| Warfarin Sodium | Warfarin Sodium | 51 | 12 |
| Rybelsus | Semaglutide | 50 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 14 |
| Atenolol | Atenolol | 47 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 15 |
| Indapamide | Indapamide | 47 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 11 |
| Levetiracetam | Levetiracetam | 47 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 47 | 11 |
| Buspirone Hcl | Buspirone Hcl | 46 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | suppressed |
| Irbesartan | Irbesartan | 44 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 14 |
| Donepezil Hcl | Donepezil Hcl | 42 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 13 |
| Montelukast Sodium | Montelukast Sodium | 38 | 13 |
| Verapamil Er | Verapamil Hcl | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 25 |
| Sucralfate | Sucralfate | 36 | 13 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 29 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | 11 |
| Felodipine Er | Felodipine | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 23 |
| Risperidone | Risperidone | 29 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Nystatin | Nystatin | 27 | 17 |
| Linzess | Linaclotide | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 21 |
| Metronidazole | Metronidazole | 25 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 11 |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 11 |
| Brilinta | Ticagrelor | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $624.21 · 33 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, CT THROMBECTOMY SYSTEM KIT, FARXIGA, FLOWTRIEVER CATHETER, S, FREESTYLE LIBRE 3, INSPIRE, MOUNJARO, Ozempic, QULIPTA, REXULTI, Rybelsus, VYEPTI, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error